1 results match your criteria: "Osaka Prefectural Habikino Hospital and Kinki University School of Medicine[Affiliation]"
Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
J Clin Oncol
August 2000
Departments of Internal Medicine, Osaka Prefectural Habikino Hospital and Kinki University School of Medicine, Osaka, Japan.
Purpose: We conducted a phase I trial of docetaxel, a new antimicrotubule agent, combined with irinotecan (CPT-11), a topoisomerase I inhibitor. The aim was to determine the maximum-tolerated dose (MTD) of docetaxel combined with CPT-11, as well as the dose-limiting toxicities (DLTs) of this combination in advanced non-small-cell lung cancer (NSCLC) patients.
Patients And Methods: Thirty-two patients with stage IIIB or IV NSCLC were treated at 4-week intervals with docetaxel (60 minutes, day 2) plus CPT-11 (90 minutes, days 1, 8, and 15).